A Study of CI-1012 in HIV-Infected Patients
Phase 1
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002196
- Lead Sponsor
- Parke-Davis
- Brief Summary
The purpose of this study is to see if it is safe and effective to give CI-1012 to HIV-infected patients who do not have any symptoms of the disease. This study also examines how the body handles CI-1012.
- Detailed Description
Patients receive 2 weeks of oral CI-1012 therapy in this open-label study, with 8 patients entered at each dose level studied.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 32
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
ViRx Inc
🇺🇸San Francisco, California, United States
Central Florida Research Initiative
🇺🇸Maitland, Florida, United States
Natl Institutes of Health
🇺🇸Bethesda, Maryland, United States
ViRx Inc🇺🇸San Francisco, California, United States